Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04609332
Other study ID # OAIC 1164/20
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 10, 2020
Est. completion date November 30, 2021

Study information

Verified date July 2023
Source University of Chile
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.


Description:

To study the presence of endothelial damage and angiogenic biomarkers with major cardiovascular events, the investigators will perform an observational study to evaluate plasma biomarkers concentrations in Covid-19 patients hospitalized in critical care units. After ethical review board approval, the investigators will select 40 patients admitted to intensive care units (ICU). After patient written consent or if the participants are unable to consent, after a relative subrogated acceptance, the investigators will collect blood samples in the first 24 hrs and on the 10th day of hospitalization. Venous blood samples are collected. After obtaining all samples, serum Syndecan-1, thrombomodulin, ANG-2, FGF basic, HGF, IL-8, PDGF-BB, TIMP-1, TIMP-2, TNFα y VEGF will be determined by a researcher blinded to the patient using commercially available Elisa kits. The concentration of each biomarker at each sample time will be compared. The investigators will observe clinical outcomes after one, 3, 6, and 12 months after the hospitalization. The investigators found no previous data of this measurement in the COVID-19 scenario. In this observational study, the investigators select a sample size on convenience for the primary outcome.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date November 30, 2021
Est. primary completion date September 26, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients older than 18 years 2. Patient with a diagnosis of COVID-19 confirmed by PCR 3. Patient with radiological image suggestive of COVID-19 with pending confirmation 4. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula) 5. Need for invasive mechanical ventilation. Exclusion Criteria: 1. Patient with an image suggestive of COVID-19 with negative PCR 2. Anticoagulation users before admission for any reason.

Study Design


Intervention

Diagnostic Test:
Endothelial damage and angiogenic biomarkers
Blood samples for biomarkers study

Locations

Country Name City State
Chile Hospital Clínico de la Universidad de Chile Independencia Santiago

Sponsors (1)

Lead Sponsor Collaborator
University of Chile

Country where clinical trial is conducted

Chile, 

References & Publications (1)

Maldonado F, Morales D, Diaz-Papapietro C, Valdes C, Fernandez C, Valls N, Lazo M, Espinoza C, Gonzalez R, Gutierrez R, Jara A, Romero C, Cerda O, Caceres M. Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Syndecan-1 concentration at 10th day Elevation of plasma Syndecan-1 24 Hours, 10 Days
Secondary Change from Baseline ANG-2 concentration at 10th day Elevation of plasma ANG-2 24 Hours, 10 Days
Secondary Change from Baseline FGF basic concentration at 10th day Elevation of plasma FGF basic 24 Hours, 10 Days
Secondary Change from Baseline HGF concentration at 10th day Elevation of plasma HGF 24 Hours, 10 Days
Secondary Change from Baseline IL-8 concentration at 10th day Elevation of plasma IL-8 24 Hours, 10 Days
Secondary Change from Baseline PDGF-BB concentration at 10th day Elevation of plasma PDGF-BB 24 Hours, 10 Days
Secondary Change from Baseline TIMP-1 concentration at 10th day Elevation of plasma TIMP-1 24 Hours, 10 Days
Secondary Change from Baseline TIMP-2 concentration at 10th day Elevation of plasma TIMP-2 24 Hours, 10 Days
Secondary Change from Baseline TNFa concentration at 10th day Elevation of plasma TNFa 24 Hours, 10 Days
Secondary Change from Baseline VEGF concentration at 10th day Elevation of plasma VEGF 24 Hours, 10 Days
Secondary Change from Baseline Thrombomodulin concentration at 10th day Elevation of plasma Thrombomodulin 24 Hours, 10 Days
Secondary Major cardiovascular events Acute coronary syndrome, myocardial injury, pulmonary embolism, and death. 1 month, 3 months, 6 months 12 months.
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3